FDA will ensure that the guidance document associated with this final rule displays the PRA burden statement toward the beginning of the document.
Inventory as of this Action
Requested
Previously Approved
05/31/2010
36 Months From Approved
1,228
0
0
63,561
0
0
0
0
0
The final rule requires manufacturers to assess the effect of a manufacturing change on the identy, strength, quality, purity and potency of a drug as those factors relate to safety or effectiveness . It addresses changes requiring submission and approval of a supplement in the following situations: before the distribution of the drug made using the change, at least 30 days prior the distribution of the drug,at the time of distribution of the drug, and changes to be described in an annual report.
The FDA with this final rule, amends its regulations on supplements and other changes to approved NADA and ANADA to implement the manufacturing changes provisions of the Food and Drug Administration Modernization Act (FDAMA 116), of 1997. These new information collection requirements for this final rule are program changes (increase), due to agency discretion caused by changing regulations.
$2
No
No
Uncollected
Uncollected
Uncollected
Uncollected
Saleda Perryman
No
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.